In order to provide you with relevant and meaningful content we need to know more about you.
Please choose the category that best describes you.
This content is intended for U.S. Healthcare Professionals. Would you like to proceed?
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
Revised May 2019
Ethosuximide is indicated for the control of absence (petit mal) epilepsy.
Ethosuximide is administered by the oral route. The initial dose for patients 3 to 6 years of age is one teaspoonful (250 mg) per day; for patients 6 years of age and...
Ethosuximide should not be used in patients with a history of hypersensitivity to succinimides.
Blood dyscrasias, including some with fatal outcome, have been reported to be associated with the use of ethosuximide; therefore, periodic...
Body As A Whole: Allergic reaction, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
Gastrointestinal System: Gastrointestinal symptoms...
Acute overdoses may produce nausea, vomiting, and CNS depression including coma with respiratory depression. A relationship between ethosuximide toxicity and its plasma levels has not been established. The...
Ethosuximide is an anticonvulsant succinimide, chemically designated as alpha-ethyl-alpha-methyl-succinimide, with the following structural formula:
Ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of...
Ethosuximide is supplied as:
NDC 59762-2350-5: 1 pint amber glass bottles.
NDC 59762-2350-6: 1 pint amber polyethylene terephthalate (PET) bottles.
Each 5 mL of oral...
Capsules, Oral Solution
Read this Medication Guide before you start taking ethosuximide and each time you get a refill. There may...
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at https://vaers.hhs.gov or call (800) 822-7967.